Abstract
Abstract
Background
The identification of novel toxins from overlooked and taxonomically exceptional species bears potential for various pharmacological applications. The remipede Xibalbanus tulumensis, an underwater cave-dwelling crustacean, is the only crustacean for which a venom system has been described. Its venom contains several xibalbin peptides that have an inhibitor cysteine knot (ICK) scaffold.
Results
Our screenings revealed that all tested xibalbin variants particularly inhibit potassium channels. Xib1 and xib13 with their eight-cysteine domain similar to spider knottins also inhibit voltage-gated sodium channels. No activity was noted on calcium channels. Expanding the functional testing, we demonstrate that xib1 and xib13 increase PKA-II and Erk1/2 sensitization signaling in nociceptive neurons, which may initiate pain sensitization. Our phylogenetic analysis suggests that xib13 either originates from the common ancestor of pancrustaceans or earlier while xib1 is more restricted to remipedes. The ten-cysteine scaffolded xib2 emerged from xib1, a result that is supported by our phylogenetic and machine learning-based analyses.
Conclusions
Our functional characterization of synthesized variants of xib1, xib2, and xib13 elucidates their potential as inhibitors of potassium channels in mammalian systems. The specific interaction of xib2 with Kv1.6 channels, which are relevant to treating variants of epilepsy, shows potential for further studies. At higher concentrations, xib1 and xib13 activate the kinases PKA-II and ERK1/2 in mammalian sensory neurons, suggesting pain sensitization and potential applications related to pain research and therapy. While tested insect channels suggest that all probably act as neurotoxins, the biological function of xib1, xib2, and xib13 requires further elucidation. A novel finding on their evolutionary origin is the apparent emergence of X. tulumensis-specific xib2 from xib1. Our study is an important cornerstone for future studies to untangle the origin and function of these enigmatic proteins as important components of remipede but also other pancrustacean and arthropod venoms.
Funder
LOEWE TBG
São Paulo Research Foundation
F.W.O.-Vlaanderen
KU Leuven funding
EU COST Action
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Publisher
Springer Science and Business Media LLC
Reference146 articles.
1. Holford M, Daly M, King GF, Norton RS. Venoms to the rescue. Science. 2018;361(6405):842–4. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=30166472&retmode=ref&cmd=prlinks.
2. von Reumont BM, Anderluh G, Antunes A, Ayvazyan N, Beis D, Caliskan F, et al. Modern venomics—current insights, novel methods, and future perspectives in biological and applied animal venom research. GigaScience. 2022;11:1–27. https://doi.org/10.1093/gigascience/giac048.
3. King GF. Tying pest insects in knots: the deployment of spider-venom-derived knottins as bioinsecticides. Pest Manag Sci. 2019;75(9):2437–45. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/ps.5452.
4. King G. Venoms to Drugs. Cambridge, UK: Royal Society of Chemistry; 2015. (Venom as a Source for the Development of Human Therapeutics). Available from: http://books.google.de/books?id=Gb-ZBgAAQBAJ&printsec=frontcover&dq=Venoms+to+Drugs&hl=&cd=1&source=gbs_api.
5. de Castro Figueiredo Bordon K, Cologna CT, Fornari-Baldo EC, Pinheiro-Júnior EL, Cerni FA, Amorim FG, et al. From animal poisons and venoms to medicines: achievements, challenges and perspectives in drug discovery. Front Pharmacol. 2020;11(1132):1–29. Available from: https://www.frontiersin.org/articles/10.3389/fphar.2020.01132.